Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

22 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Aggrenox Articles

Boehringer's 2008 net sales jump 6.4%

24 April 2009

Nippon Boeh Ing again records fastest growth in Japan's ethical drug market

28 April 2008

Spiriva and Micardis boost Boehringer's 2007 sales 8.8%, as profit jumps 4.8% to $2.8M

14 April 2008

Barr challenges Boeh Ing's Aggrenox patent

23 July 2007

R&D continues to be key for Germany's Boehringer Ingelheim

2 April 2007

Record growth for Boeh Ing Japan

1 May 2006

Boeh Ingelheim launches largest-ever stroke prevention trial with dipyridamole

2 June 2003

Boeh Ingelheim starts two mega-trials

24 February 2003

BI's Aggrenox OKed in USA

25 November 1999

Aggrenox recommended

29 April 1999

BI granted a priority review for Aggrenox

4 March 1999

Showing 1-11 of 11 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Is failure to adopt business process management putting the pharma industry at risk?
  • New Zealand declines Alexion's funding application for Solaris
  • HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
  • Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
  • Elan makes "transformational" acquisitions and a divestment
  • Is failure to adopt business process management putting the pharma industry at risk?
  • New Zealand declines Alexion's funding application for Solaris
  • HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
  • Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
  • Elan makes "transformational" acquisitions and a divestment

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS